Limit search to items available for checkout
E-BOOK
Title Cancer biomarkers (Barh)
Cancer biomarkers : minimal and noninvasive early diagnosis and prognosis / edited by Debmalya Barh, Angelo Carpi, Mukesh Verma, Mehmet Gunduz.
Imprint Boca Raton : CRC Press/Taylor & Francis Group, [2014]
©2014

Copies/Volumes

LOCATION CALL # STATUS
 Internet  Electronic Book    AVAILABLE
Description 1 online resource (954 pages) : illustrations
Bibliog. Includes bibliographical references.
Note Available only to authorized UTEP users.
Online resource; title from digital title page (ebrary, viewed on December 23, 2014).
Subject Tumor markers.
Cancer -- Diagnosis.
Cancer -- Treatment.
Biomarkers, Tumor.
Early Detection of Cancer.
Neoplasms -- diagnosis.
Neoplasms -- therapy.
Genre Electronic books.
Contents Part I. General and technical aspects. Quality control and ethical issues of cancer biomarker discovery -- Imaging techniques in cancer diagnosis -- Role of pet in cancer diagnosis -- Innovative tools for early detection of cancer -- Noninvasive nanodiagnostics for cancer -- Mitochondrial DNA in early cancer diagnosis and screening -- Circulating miRNA biomarkers in various solid cancers -- Stem cell biomarkers in early diagnosis, prognosis, and therapy of cancer -- Salivary biomarkers in early diagnosis and monitoring of cancer -- Part II. Brain and head and neck cancers. Biomarkers for brain gliomas -- Noninvasive biomarkers in head and neck squamous cell carcinoma -- Biological markers in oral squamous cell carcinoma -- Part III. Gastrointestinal cancers. Biomarkers for gastric cancer and the related premalignant conditions -- Biomarkers in esophageal adenocarcinoma -- Biomarkers for diagnosis and metastasis of hepatocellular carcinoma -- Noninvasive early markers in gallbladder cancer -- Noninvasive early markers in pancreatic cancer -- Part IV. Lung cancer and mesothelioma. Noninvasive early markers in lung cancer -- Exhaled volatile organic compounds as noninvasive early molecular markers in lung cancer: bridging the gap from bench to bedside -- Part V. Urological cancers. Noninvasive early molecular biomarkers in kidney cancer -- Novel oncomarkers used for earlier detection of bladder carcinoma -- Screening for prostate cancer: new markers and future aspects -- Part VI. Gynecological and endocrine cancers. Early biomarkers in breast cancer -- Noninvasive biomarkers in ovarian cancer -- Early markers for neoplastic lesions of the uterine cervix -- Biomarkers in diagnosis of papillary thyroid carcinoma -- Biomolecular markers for improving management of follicular and medullary thyroid cancer -- Part VII. Hematological cancers. Biomarkers in myelodysplastic syndrome -- Markers for diagnosis, prognosis, and therapy of acute myeloid leukemia -- Biomarkers in Hodgkin's lymphoma -- Multiple myeloma and evolution of novel biomarkers and therapies -- Part VIII. Melanoma. Diagnostic and prognostic biomarkers in cutaneous melanoma.
Summary "According to the American Cancer Society report, "by 2030, the global cancer burden is expected to nearly double, growing to 21.4 million cases and 13.2 million deaths." Early diagnosis improves treatment efficacy and quality of life as well as reduces the cost for disease management. However, the development of molecular markers for early cancer diagnosis is always a challenge. Some fundamental principles in medical practice are (a) primum non nocere, a Latin phrase that means "first, do no harm," and (b) even when a patient's prognosis is poor, the physician must do his or her best for improving quality of the patient's life. Therefore, noninvasive or minimally invasive cancer diagnostic methods are of choice that can avoid complications of biopsy and other unfavorable impacts on patient's health. In this context, patients' easily collectable biospecimens such as blood, serum, plasma, urine, stool, sputum, saliva, etc.-based molecular markers having high specificity and sensitivity in early diagnosis are emerging rapidly and in many instances such markers are also emerging as next-generation prognostic indicators and personalized therapeutics and precision medicine. Several patents have been filed and/or granted on such markers, and a number of health-care companies and authorities currently use or focus on the development of such markers. The significance of clinical validation approaches of several markers has been discussed in different chapters. This book, Cancer Biomarkers: Noninvasive Early Diagnosis and Prognosis, reflects the rapid expansion of important scientific, technological, clinical, and translational aspects of noninvasive or minimally invasive molecular cancer biomarkers and their applications along with other conventional markers"--Provided by publisher.
Other Author Barh, Debmalya, editor.
Carpi, A. (Angelo), editor.
Verma, Mukesh, editor.
Gunduz, Mehmet, editor.
Other Title Print version: Cancer biomarkers : minimal and noninvasive early diagnosis and prognosis. Boca Raton : Taylor & Francis, [2014] xxiii, 927 pages 9781466584280